{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:00:00Z","timestamp":1783947600348,"version":"3.55.0"},"reference-count":176,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11154-026-10027-8","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:42:40Z","timestamp":1778046160000},"page":"213-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction\u2013associated steatotic liver disease (MASLD) and metabolic dysfunction\u2013associated steatohepatitis (MASH)"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0625-6667","authenticated-orcid":false,"given":"Roberto","family":"Vettor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idit","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gadi","family":"Lalazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Haluz\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Wendy","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel A.","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Abaalkhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah","family":"Abusnana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radan","family":"Bruha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariann","family":"Harangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Jazzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Kukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Lambadiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ria","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Petta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina Silvia","family":"Pop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca Pantea","family":"Stoian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Tomasiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"3","key":"10027_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J Hepatol"},{"issue":"1","key":"10027_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-025-00871-1","volume":"5","author":"J Boeckmans","year":"2025","unstructured":"Boeckmans J, Hagstrom H, Cryer DR, Schattenberg JM. The importance of patient engagement in the multimodal treatment of MASLD. Commun Med. 2025;5(1):148. https:\/\/doi.org\/10.1038\/s43856-025-00871-1.","journal-title":"Commun Med"},{"key":"10027_CR3","doi-asserted-by":"publisher","DOI":"10.37349\/emed.2025.1001281","volume":"6","author":"LE Adinolfi","year":"2025","unstructured":"Adinolfi LE, Marrone A, Rinaldi L, Nevola R, Izzi A, Sasso FC. Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management. Explor Med. 2025;6:1001281.","journal-title":"Explor Med"},{"issue":"6","key":"10027_CR4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"issue":"4","key":"10027_CR5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","journal-title":"Hepatology"},{"key":"10027_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155958","volume":"158","author":"P Danpanichkul","year":"2024","unstructured":"Danpanichkul P, Suparan K, Dutta P, Kaeosri C, Sukphutanan B, Pang Y, et al. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019. Metabolism. 2024;158:155958. https:\/\/doi.org\/10.1016\/j.metabol.2024.155958.","journal-title":"Metabolism"},{"issue":"6","key":"10027_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70132","volume":"8","author":"DM Miller","year":"2025","unstructured":"Miller DM, McCauley KF, Dunham-Snary KJ. Metabolic dysfunction-associated steatotic liver disease (MASLD): mechanisms, clinical implications and therapeutic advances. Endocrinol Diabetes Metab. 2025;8(6):e70132. https:\/\/doi.org\/10.1002\/edm2.70132.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"11","key":"10027_CR8","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","volume":"72","author":"E En Li Cho","year":"2023","unstructured":"En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138\u201348. https:\/\/doi.org\/10.1136\/gutjnl-2023-330110.","journal-title":"Gut"},{"issue":"10","key":"10027_CR9","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22(10):1999-2010 e8. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.006.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10027_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5114\/ceh.2023.130744","volume":"9","author":"AE Platek","year":"2023","unstructured":"Platek AE, Szymanska A. Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor. Clin Exp Hepatol. 2023;9(3):187\u201392. https:\/\/doi.org\/10.5114\/ceh.2023.130744.","journal-title":"Clin Exp Hepatol"},{"issue":"Suppl","key":"10027_CR11","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2024;31(Suppl):S32-50. https:\/\/doi.org\/10.3350\/cmh.2024.0431.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10027_CR12","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jhep.2024.09.027","volume":"82","author":"Z Li","year":"2025","unstructured":"Li Z, Li Z, Cao D, Hu Y. Is MASLD a real culprit for all-cause mortality? A meta-analysis and preliminary pathophysiology exploration in the real world. J Hepatol. 2025;82(1):e29\u201331. https:\/\/doi.org\/10.1016\/j.jhep.2024.09.027.","journal-title":"J Hepatol"},{"issue":"6","key":"10027_CR13","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1016\/j.jhep.2024.02.010","volume":"80","author":"R Hashida","year":"2024","unstructured":"Hashida R, Nakano D, Kawaguchi M, Younossi ZM, Kawaguchi T. Changing from NAFLD to MASLD: the implications for health-related quality of life data. J Hepatol. 2024;80(6):e249-51. https:\/\/doi.org\/10.1016\/j.jhep.2024.02.010.","journal-title":"J Hepatol"},{"issue":"2","key":"10027_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/hep.0000000000000735","volume":"82","author":"S Driessen","year":"2025","unstructured":"Driessen S, Francque SM, Anker SD, Castro Cabezas M, Grobbee DE, Tushuizen ME, et al. Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology. 2025;82(2):487\u2013503. https:\/\/doi.org\/10.1097\/hep.0000000000000735.","journal-title":"Hepatology"},{"issue":"2","key":"10027_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan N, Yki-J\u00e4rvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 2025;13(2):134\u201348. https:\/\/doi.org\/10.1016\/S2213-8587(24)00318-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10027_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101271","volume":"7","author":"G Feng","year":"2025","unstructured":"Feng G, Targher G, Byrne CD, Yilmaz Y, Wai-Sun Wong V, Adithya Lesmana CR, et al. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep. 2025;7(3):101271. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101271.","journal-title":"JHEP Rep"},{"issue":"7","key":"10027_CR17","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ueg2.70072","volume":"13","author":"P Danpanichkul","year":"2025","unstructured":"Danpanichkul P, Suparan K, Diaz LA, Fallon MB, Chen VL, Namsathimaphorn K, et al. The rising global burden of MASLD and other metabolic diseases (2000\u20132021). United Eur Gastroenterol J. 2025;13(7):1141\u201354. https:\/\/doi.org\/10.1002\/ueg2.70072.","journal-title":"United Eur Gastroenterol J"},{"issue":"8","key":"10027_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000488","volume":"8","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Mangla KK, Chandramouli AS, Lazarus JV. Estimating the economic impact of comorbidities in patients with MASH and defining high-cost burden in patients with noncirrhotic MASH. Hepatol Commun. 2024;8(8):e0488. https:\/\/doi.org\/10.1097\/HC9.0000000000000488.","journal-title":"Hepatol Commun"},{"issue":"6","key":"10027_CR19","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.numecd.2020.02.016","volume":"30","author":"S Petta","year":"2020","unstructured":"Petta S, Ting J, Saragoni S, Degli Esposti L, Shreay S, Petroni ML, et al. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. Nutr Metab Cardiovasc Dis. 2020;30(6):1014\u201322. https:\/\/doi.org\/10.1016\/j.numecd.2020.02.016.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10027_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2147\/ceor.S472446","volume":"16","author":"E Torre","year":"2024","unstructured":"Torre E, Di Matteo S, Martinotti C, Bruno GM, Goglia U, Testino G, et al. Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives. Clinicoecon Outcomes Res. 2024;16:773\u201384. https:\/\/doi.org\/10.2147\/ceor.S472446.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"10027_CR21","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s12072-021-10182-x","volume":"15","author":"FM Sanai","year":"2021","unstructured":"Sanai FM, Al Khathlan A, Al Fadhli A, Jazzar AS, Hashim AM, Mansour E, et al. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait. Hepatol Int. 2021;15(4):912\u201321. https:\/\/doi.org\/10.1007\/s12072-021-10182-x.","journal-title":"Hepatol Int"},{"issue":"4","key":"10027_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16120","volume":"45","author":"F Lu","year":"2025","unstructured":"Lu F, Liu J, She B, Yang H, Ji F, Zhang L. Global trends and inequalities of liver complications related to metabolic dysfunction-associated steatotic liver disease: an analysis from 1990 to 2021. Liver Int. 2025;45(4):e16120. https:\/\/doi.org\/10.1111\/liv.16120.","journal-title":"Liver Int"},{"issue":"2","key":"10027_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16224","volume":"45","author":"L Castera","year":"2025","unstructured":"Castera L, Alazawi W, Bugianesi E, Caussy C, Federici M, Romero-Gomez M, et al. A European survey to identify challenges in the management of metabolic dysfunction-associated steatotic liver disease. Liver Int. 2025;45(2):e16224. https:\/\/doi.org\/10.1111\/liv.16224.","journal-title":"Liver Int"},{"issue":"7","key":"10027_CR24","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/ueg2.12445","volume":"11","author":"S Driessen","year":"2023","unstructured":"Driessen S, de Jong VD, van Son KC, Klompenhouwer T, Colardelle Y, Alings M, et al. A global survey of health care workers\u2019 awareness of non-alcoholic fatty liver disease: the AwareNASH survey. United Eur Gastroenterol J. 2023;11(7):654\u201362. https:\/\/doi.org\/10.1002\/ueg2.12445.","journal-title":"United Eur Gastroenterol J"},{"key":"10027_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1407389","volume":"11","author":"JH Lee","year":"2024","unstructured":"Lee JH, Yoon EL, Oh JH, Kim K, Ahn SB, Jun DW. Barriers to care linkage and educational impact on unnecessary MASLD referrals. Front Med (Lausanne). 2024;11:1407389. https:\/\/doi.org\/10.3389\/fmed.2024.1407389.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"10027_CR26","first-page":"568","volume":"19","author":"M Noureddin","year":"2023","unstructured":"Noureddin M. Utilization of noninvasive tests to diagnose at-risk metabolic dysfunction-associated steatohepatitis. Gastroenterol Hepatol (N Y). 2023;19(9):568\u201370.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"10","key":"10027_CR27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.14218\/JCTH.2025.00286","volume":"13","author":"M El-Kassas","year":"2025","unstructured":"El-Kassas M, AlNaamani KM, Khalifa R, Yilmaz Y, Labidi A, Almattooq M, et al. Mapping metabolic dysfunction-associated steatotic liver disease models of care across 17 Middle East and North Africa countries: insights into guidelines, infrastructure, and referral systems. J Clin Transl Hepatol. 2025;13(10):791\u2013808. https:\/\/doi.org\/10.14218\/JCTH.2025.00286.","journal-title":"J Clin Transl Hepatol"},{"key":"10027_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000678","author":"AM Allen","year":"2025","unstructured":"Allen AM, Lazarus JV, Alkhouri N, Noureddin M, Wong VW, Tsochatzis EA, et al. Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction-associated steatotic liver disease. Hepatol Commun. 2025;9(5). https:\/\/doi.org\/10.1097\/HC9.0000000000000678.","journal-title":"Hepatol Commun"},{"key":"10027_CR29","unstructured":"American Association for the Study of Liver Diseases. New MASLD nomenclature 2023. Available from: https:\/\/www.aasld.org\/new-masld-nomenclature. [Cited 2025 Dec]."},{"key":"10027_CR30","doi-asserted-by":"publisher","DOI":"10.37349\/emed.2025.1001365","volume":"6","author":"C Acierno","year":"2025","unstructured":"Acierno C, Nevola R, Barletta F, Zieli\u0144ska K, Rinaldi L, Sasso FC, et al. The transition from NAFLD to MASLD: implications for diagnosis, prognosis, and clinical management. Exploration of Medicine. 2025;6:1001365. https:\/\/doi.org\/10.37349\/emed.2025.1001365.","journal-title":"Exploration of Medicine"},{"issue":"2","key":"10027_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000386","volume":"8","author":"H Hagstrom","year":"2024","unstructured":"Hagstrom H, Adams LA, Allen AM, Byrne CD, Chang Y, Duseja A, et al. The future of international classification of diseases coding in steatotic liver disease: an expert panel Delphi consensus statement. Hepatol Commun. 2024;8(2):e0386. https:\/\/doi.org\/10.1097\/HC9.0000000000000386.","journal-title":"Hepatol Commun"},{"issue":"5","key":"10027_CR32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.5009\/gnl250072","volume":"19","author":"JH Lee","year":"2025","unstructured":"Lee JH, Ahn SH, Park J, Jeon SY, Yoon EL, Lee HS, et al. Misclassification of alcohol use disorder in MASLD and MetALD: prevalence, clinical characteristics, and outcomes. Gut Liver. 2025;19(5):735\u201345. https:\/\/doi.org\/10.5009\/gnl250072.","journal-title":"Gut Liver"},{"key":"10027_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2023-300852","author":"ME Crozier","year":"2023","unstructured":"Crozier ME, Farokhnia M, Persky S, Leggio L, Curtis B. Relationship between self-stigma about alcohol dependence and severity of alcohol drinking and craving. BMJ Ment Health. 2023;26(1). https:\/\/doi.org\/10.1136\/bmjment-2023-300852.","journal-title":"BMJ Ment Health"},{"issue":"1","key":"10027_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66257-w","volume":"14","author":"A Hajebi","year":"2024","unstructured":"Hajebi A, Nasserinejad M, Rezaei N, Azadnajafabad S, Rashidi MM, Ahmadi N, et al. Alcohol consumption among Iranian population based on the findings of STEPS survey 2021. Sci Rep. 2024;14(1):16819. https:\/\/doi.org\/10.1038\/s41598-024-66257-w.","journal-title":"Sci Rep"},{"key":"10027_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104028","volume":"116","author":"J Manthey","year":"2023","unstructured":"Manthey J, Braddick F, Lopez-Pelayo H, Shield K, Rehm J, Kilian C. Unrecorded alcohol use in 33 European countries: analyses of a comparative survey with 49,000 people who use alcohol. Int J Drug Policy. 2023;116:104028. https:\/\/doi.org\/10.1016\/j.drugpo.2023.104028.","journal-title":"Int J Drug Policy"},{"key":"10027_CR36","unstructured":"U.S. Food and Drug Administration. REZDIFFRA\u00ae prescribing information. Silver Spring (MD): FDA. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217785s000lbl.pdf. [Cited 2025 Jun]."},{"key":"10027_CR37","unstructured":"European Medicines Agency. REZDIFFRA\u00ae: CHMP summary of positive opinion. Amsterdam: EMA. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-rezdiffra_en.pdf. [Cited 2025 Sep]."},{"key":"10027_CR38","unstructured":"U.S. Food and Drug Administration. Wegovy\u00ae prescribing information. Silver Spring (MD): FDA. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s024lbl.pdf. [Cited 2025 Aug]."},{"issue":"11","key":"10027_CR39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.42750","volume":"8","author":"JV Lazarus","year":"2025","unstructured":"Lazarus JV, Agirre-Garrido L, Diaz LA, Danpanichkul P, Kivuyo SL, Kondili LA, et al. Cost-effectiveness of MASH diagnosis and management approaches among those with type 2 diabetes. JAMA Netw Open. 2025;8(11):e2542750. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.42750.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10027_CR40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/13696998.2025.2459529","volume":"28","author":"P McEwan","year":"2025","unstructured":"McEwan P, Bog M, Faurby M, Foos V, Lingvay I, Lubker C, et al. Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes. J Med Econ. 2025;28(1):268\u201378. https:\/\/doi.org\/10.1080\/13696998.2025.2459529.","journal-title":"J Med Econ"},{"key":"10027_CR41","unstructured":"World Health Organization. WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults. Geneva: WHO. 2024. Available from: https:\/\/files.magicapp.org\/guideline\/5f0963f2-daa8-4d20-b0fc-eab3bcf69c48\/published_guideline_10802-1_0.pdf. [Cited 2025 Dec]"},{"issue":"3","key":"10027_CR42","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VW Wong","year":"2023","unstructured":"Wong VW, Ekstedt M, Wong GL, Hagstrom H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842\u201352. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.036.","journal-title":"J Hepatol"},{"issue":"2","key":"10027_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101903","volume":"30","author":"LA Diaz","year":"2025","unstructured":"Diaz LA, Arab JP, Idalsoaga F, Perelli J, Vega J, Dirchwolf M, et al. Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group. Ann Hepatol. 2025;30(2):101903. https:\/\/doi.org\/10.1016\/j.aohep.2025.101903.","journal-title":"Ann Hepatol"},{"issue":"11","key":"10027_CR44","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.cgh.2023.12.033","volume":"22","author":"S Pelusi","year":"2024","unstructured":"Pelusi S, Ronzoni L, Rondena J, Rosso C, Pennisi G, Dongiovanni P, et al. Prevalence and determinants of liver disease in relatives of Italian patients with advanced MASLD. Clin Gastroenterol Hepatol. 2024;22(11):2231-9.e4. https:\/\/doi.org\/10.1016\/j.cgh.2023.12.033.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10027_CR45","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4103\/tcmj.tcmj_232_24","volume":"37","author":"YM Cheng","year":"2025","unstructured":"Cheng YM, Wang SW, Wang C, Wang CC. Unmet needs of metabolic dysfunction - associated fatty or steatotic liver disease. Tzu Chi Med J. 2025;37(2):152\u20136. https:\/\/doi.org\/10.4103\/tcmj.tcmj_232_24.","journal-title":"Tzu Chi Med J"},{"key":"10027_CR46","doi-asserted-by":"publisher","DOI":"10.54394\/CJQU6666","volume-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024."},{"issue":"2","key":"10027_CR47","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jvh.13955","volume":"31","author":"E Vo-Quang","year":"2024","unstructured":"Vo-Quang E, Lemoine M. Global elimination of HBV: is it really achievable? J Viral Hepat. 2024;31(2):4\u201312. https:\/\/doi.org\/10.1111\/jvh.13955.","journal-title":"J Viral Hepat"},{"key":"10027_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8101526","author":"H Hanif","year":"2020","unstructured":"Hanif H, Khan MM, Ali MJ, Shah PA, Satiya J, Lau DTY, et al. A new endemic of concomitant nonalcoholic fatty liver disease and chronic hepatitis B. Microorganisms. 2020;8(10). https:\/\/doi.org\/10.3390\/microorganisms8101526.","journal-title":"Microorganisms"},{"issue":"1","key":"10027_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-91013-z","volume":"15","author":"L Long","year":"2025","unstructured":"Long L, Wu Y, Tang H, Xiao Y, Wang M, Shen L, et al. Development and validation of a scoring system to predict MASLD patients with significant hepatic fibrosis. Sci Rep. 2025;15(1):9639. https:\/\/doi.org\/10.1038\/s41598-025-91013-z.","journal-title":"Sci Rep"},{"issue":"21s","key":"10027_CR50","first-page":"848","volume":"14","author":"S Aravinth","year":"2025","unstructured":"Aravinth S, Mohan Rao VR, Sobia PR. A prospective cross-sectional study to evaluate the utility of Fibroscan and serum biomarkers (APRI, FIB-4) for non-invasive diagnosis of liver fibrosis in metabolic dysfunction associated fatty liver disease (MAFLD) patients in a tertiary care center. J Neonatal Surg. 2025;14(21s):848\u201354.","journal-title":"J Neonatal Surg"},{"issue":"9","key":"10027_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70281","volume":"45","author":"M Franck","year":"2025","unstructured":"Franck M, John K, Rau M, Geier A, Sowa JP, Schattenberg JM, et al. Limitations of guideline-recommended risk stratification in identifying MASLD patients for novel drug treatments. Liver Int. 2025;45(9):e70281. https:\/\/doi.org\/10.1111\/liv.70281.","journal-title":"Liver Int"},{"issue":"5","key":"10027_CR52","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","volume":"112","author":"S McPherson","year":"2017","unstructured":"McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740\u201351. https:\/\/doi.org\/10.1038\/ajg.2016.453.","journal-title":"Am J Gastroenterol"},{"key":"10027_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10100842","author":"Y Seko","year":"2020","unstructured":"Seko Y, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, et al. The appropriate opportunity for evaluating liver fibrosis by using the FIB-4 index in patients with nonalcoholic fatty liver disease in Japan. Diagnostics (Basel). 2020;10(10). https:\/\/doi.org\/10.3390\/diagnostics10100842.","journal-title":"Diagnostics"},{"issue":"4","key":"10027_CR54","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.jhep.2022.06.016","volume":"77","author":"L Gracen","year":"2022","unstructured":"Gracen L, Hayward KL, Irvine KM, Valery PC, Powell EE. Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosis. J Hepatol. 2022;77(4):1219\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.016.","journal-title":"J Hepatol"},{"issue":"3","key":"10027_CR55","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/hepr.13737","volume":"52","author":"H Park","year":"2022","unstructured":"Park H, Yoon EL, Kim M, Lee J, Kim JH, Cho S, et al. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era. Hepatol Res. 2022;52(3):247\u201354. https:\/\/doi.org\/10.1111\/hepr.13737.","journal-title":"Hepatol Res"},{"issue":"11","key":"10027_CR56","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.4254\/wjh.v13.i11.1688","volume":"13","author":"MA Kalas","year":"2021","unstructured":"Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: a review for clinicians. World J Hepatol. 2021;13(11):1688\u201398. https:\/\/doi.org\/10.4254\/wjh.v13.i11.1688.","journal-title":"World J Hepatol"},{"issue":"1","key":"10027_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-43028-7","volume":"13","author":"J Huang","year":"2023","unstructured":"Huang J, Gao T, Zhang H, Wang X. Association of obesity profiles and metabolic health status with liver injury among US adult population in NHANES 1999\u20132016. Sci Rep. 2023;13(1):15958. https:\/\/doi.org\/10.1038\/s41598-023-43028-7.","journal-title":"Sci Rep"},{"issue":"10406","key":"10027_CR58","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/s0140-6736(23)01174-1","volume":"402","author":"M Serra-Burriel","year":"2023","unstructured":"Serra-Burriel M, Juanola A, Serra-Burriel F, Thiele M, Graupera I, Pose E, et al. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet. 2023;402(10406):988\u201396. https:\/\/doi.org\/10.1016\/s0140-6736(23)01174-1.","journal-title":"Lancet"},{"issue":"4","key":"10027_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2025.102512","volume":"15","author":"LA van Kleef","year":"2025","unstructured":"van Kleef LA, Pustjens J, Janssen HLA, Brouwer WP. Diagnostic accuracy of the LiverRisk score to detect increased liver stiffness among a United States general population and subgroups. J Clin Exp Hepatol. 2025;15(4):102512. https:\/\/doi.org\/10.1016\/j.jceh.2025.102512.","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"10027_CR60","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/s2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362\u201373. https:\/\/doi.org\/10.1016\/s2468-1253(19)30383-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10027_CR61","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.cgh.2023.02.003","volume":"21","author":"E Truong","year":"2023","unstructured":"Truong E, Gornbein JA, Yang JD, Noureddin N, Harrison SA, Alkhouri N, et al. MRI-AST (MAST) score accurately predicts major adverse liver outcome, hepatocellular carcinoma, liver transplant, and liver-related death. Clin Gastroenterol Hepatol. 2023;21(10):2570-7.e1. https:\/\/doi.org\/10.1016\/j.cgh.2023.02.003.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10027_CR62","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the Liver","year":"2021","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u2009\u2013\u20092021 update. J Hepatol. 2021;75(3):659\u201389. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025.","journal-title":"J Hepatol"},{"issue":"2","key":"10027_CR63","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14218\/jcth.2021.00188","volume":"10","author":"M Shen","year":"2022","unstructured":"Shen M, Lee A, Lefkowitch JH, Worman HJ. Vibration-controlled transient elastography for assessment of liver fibrosis at a USA academic medical center. J Clin Transl Hepatol. 2022;10(2):197\u2013206. https:\/\/doi.org\/10.14218\/jcth.2021.00188.","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10027_CR64","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/jgh.14311","volume":"34","author":"JC Chow","year":"2019","unstructured":"Chow JC, Wong GL, Chan AW, Shu SS, Chan CK, Leung JK, et al. Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. J Gastroenterol Hepatol. 2019;34(1):241\u20138. https:\/\/doi.org\/10.1111\/jgh.14311.","journal-title":"J Gastroenterol Hepatol"},{"key":"10027_CR65","doi-asserted-by":"publisher","unstructured":"Hasanoglu I, Rivero-Juarez A, Ozkaya Sahin G, Escmid study group for viral hepatitis E. When metabolic dysfunction-associated steatotic liver disease meets viral hepatitis. J Clin Med. 2025;14(10). https:\/\/doi.org\/10.3390\/jcm14103422.","DOI":"10.3390\/jcm14103422"},{"issue":"4","key":"10027_CR66","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.cgh.2020.12.016","volume":"20","author":"K Imajo","year":"2022","unstructured":"Imajo K, Honda Y, Kobayashi T, Nagai K, Ozaki A, Iwaki M, et al. Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20(4):908-17 e11. https:\/\/doi.org\/10.1016\/j.cgh.2020.12.016.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10027_CR67","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","volume":"69","author":"R Loomba","year":"2020","unstructured":"Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut. 2020;69(7):1343\u201352. https:\/\/doi.org\/10.1136\/gutjnl-2018-317593.","journal-title":"Gut"},{"key":"10027_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12020407","author":"E Martinou","year":"2022","unstructured":"Martinou E, Pericleous M, Stefanova I, Kaur V, Angelidi AM. Diagnostic modalities of non-alcoholic fatty liver disease: from biochemical biomarkers to multi-omics non-invasive approaches. Diagnostics. 2022;12(2). https:\/\/doi.org\/10.3390\/diagnostics12020407.","journal-title":"Diagnostics"},{"key":"10027_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1499013","volume":"11","author":"S Dawod","year":"2024","unstructured":"Dawod S, Brown K. Non-invasive testing in metabolic dysfunction-associated steatotic liver disease. Front Med (Lausanne). 2024;11:1499013. https:\/\/doi.org\/10.3389\/fmed.2024.1499013.","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"10027_CR70","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.cgh.2020.04.017","volume":"18","author":"E Vilar-Gomez","year":"2020","unstructured":"Vilar-Gomez E, Lou Z, Kong N, Vuppalanchi R, Imperiale TF, Chalasani N. Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States health care system. Clin Gastroenterol Hepatol. 2020;18(10):2305-14 e12. https:\/\/doi.org\/10.1016\/j.cgh.2020.04.017.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10027_CR71","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/hep.31655","volume":"73","author":"C Cassinotto","year":"2021","unstructured":"Cassinotto C, Boursier J, Paisant A, Guiu B, Irles-Depe M, Canivet C, et al. Transient versus two-dimensional shear-wave elastography in a multistep strategy to detect advanced fibrosis in NAFLD. Hepatology. 2021;73(6):2196\u2013205. https:\/\/doi.org\/10.1002\/hep.31655.","journal-title":"Hepatology"},{"issue":"1","key":"10027_CR72","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jgh.14782","volume":"35","author":"WL Leong","year":"2020","unstructured":"Leong WL, Lai LL, Nik Mustapha NR, Vijayananthan A, Rahmat K, Mahadeva S, et al. Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2020;35(1):135\u201341. https:\/\/doi.org\/10.1111\/jgh.14782.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10027_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/jmri.26716","volume":"51","author":"YN Zhang","year":"2020","unstructured":"Zhang YN, Fowler KJ, Ozturk A, Potu CK, Louie AL, Montes V, et al. Liver fibrosis imaging: a clinical review of ultrasound and magnetic resonance elastography. J Magn Reson Imaging. 2020;51(1):25\u201342. https:\/\/doi.org\/10.1002\/jmri.26716.","journal-title":"J Magn Reson Imaging"},{"issue":"12","key":"10027_CR74","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1016\/j.ultrasmedbio.2018.07.008","volume":"44","author":"G Ferraioli","year":"2018","unstructured":"Ferraioli G, Wong VW, Castera L, Berzigotti A, Sporea I, Dietrich CF, et al. Liver ultrasound elastography: an update to the World Federation for Ultrasound in Medicine and Biology guidelines and recommendations. Ultrasound Med Biol. 2018;44(12):2419\u201340. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2018.07.008.","journal-title":"Ultrasound Med Biol"},{"issue":"4","key":"10027_CR75","doi-asserted-by":"publisher","first-page":"810","DOI":"10.17305\/bb.2024.11577","volume":"25","author":"X Xu","year":"2025","unstructured":"Xu X, Zhang Y, Zhu Q, Xie Y, Zhou Y, Dong B, et al. Diagnostic accuracy of two-dimensional shear wave elastography and point shear wave elastography in identifying different stages of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a meta-analysis. Biomol Biomed. 2025;25(4):810\u201321. https:\/\/doi.org\/10.17305\/bb.2024.11577.","journal-title":"Biomol Biomed"},{"issue":"4","key":"10027_CR76","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s00330-021-08369-9","volume":"32","author":"YN Zhang","year":"2022","unstructured":"Zhang YN, Fowler KJ, Boehringer AS, Montes V, Schlein AN, Covarrubias Y, et al. Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease. Eur Radiol. 2022;32(4):2457\u201369. https:\/\/doi.org\/10.1007\/s00330-021-08369-9.","journal-title":"Eur Radiol"},{"issue":"1","key":"10027_CR77","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/apt.18019","volume":"60","author":"DJM Bauer","year":"2024","unstructured":"Bauer DJM, Nixdorf L, Dominik N, Schwarz M, Hofer BS, Hartl L, et al. The deep abdominal ultrasound transducer (DAX) increases the success rate and diagnostic accuracy of shear wave elastography for liver fibrosis assessment in patients with obesity-a prospective biopsy-controlled study. Aliment Pharmacol Ther. 2024;60(1):70\u201382. https:\/\/doi.org\/10.1111\/apt.18019.","journal-title":"Aliment Pharmacol Ther"},{"key":"10027_CR78","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003493","author":"GP Caviglia","year":"2025","unstructured":"Caviglia GP, Ferro A, D\u2019Ambrosio R, Perbellini R, Lampertico P, Periti G, et al. Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicenter study. Am J Gastroenterol. 2025. https:\/\/doi.org\/10.14309\/ajg.0000000000003493.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10027_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16119","volume":"45","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Paik JM, Henry L, Stepanova M, Nader F. Pharmaco-economic assessment of screening strategies for high-risk MASLD in primary care. Liver Int. 2025;45(4):e16119. https:\/\/doi.org\/10.1111\/liv.16119.","journal-title":"Liver Int"},{"issue":"1","key":"10027_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-063959","volume":"13","author":"C Mettananda","year":"2023","unstructured":"Mettananda C, Egodage T, Dantanarayana C, Fernando R, Ranaweera L, Luke N, et al. Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study. BMJ Open. 2023;13(1):e063959. https:\/\/doi.org\/10.1136\/bmjopen-2022-063959.","journal-title":"BMJ Open"},{"issue":"6","key":"10027_CR81","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2337\/dc24-2075","volume":"48","author":"C Caussy","year":"2025","unstructured":"Caussy C, Verges B, Leleu D, Duvillard L, Subtil F, Abichou-Klich A, et al. Screening for metabolic dysfunction-associated steatotic liver disease-related advanced fibrosis in diabetology: a prospective multicenter study. Diabetes Care. 2025;48(6):877\u201386. https:\/\/doi.org\/10.2337\/dc24-2075.","journal-title":"Diabetes Care"},{"issue":"5","key":"10027_CR82","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2016.12.022.","journal-title":"J Hepatol"},{"issue":"3","key":"10027_CR83","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jacr.2024.12.014","volume":"22","author":"E Schonfeld","year":"2025","unstructured":"Schonfeld E, Kierans AS, Fox R, Brandman D. Using incidental radiologic findings of hepatic steatosis to improve the diagnosis of metabolic dysfunction-associated steatotic liver disease. J Am Coll Radiol. 2025;22(3):358\u201365. https:\/\/doi.org\/10.1016\/j.jacr.2024.12.014.","journal-title":"J Am Coll Radiol"},{"issue":"7","key":"10027_CR84","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.crad.2019.02.014","volume":"74","author":"ML Kromrey","year":"2019","unstructured":"Kromrey ML, Ittermann T, Berning M, Kolb C, Hoffmann RT, Lerch MM, et al. Accuracy of ultrasonography in the assessment of liver fat compared with MRI. Clin Radiol. 2019;74(7):539\u201346. https:\/\/doi.org\/10.1016\/j.crad.2019.02.014.","journal-title":"Clin Radiol"},{"key":"10027_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15202640","author":"D Kavvadas","year":"2025","unstructured":"Kavvadas D, Rafailidis V, Liakos A, Sinakos E, Partovi S, Papamitsou T, et al. Quantitative ultrasound for hepatic steatosis: a systematic review highlighting the diagnostic performance of ultrasound-derived fat fraction. Diagnostics (Basel) 2025;15(20). https:\/\/doi.org\/10.3390\/diagnostics15202640.","journal-title":"Diagnostics"},{"issue":"5","key":"10027_CR86","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/ajg.2016.49","volume":"111","author":"EB Tapper","year":"2016","unstructured":"Tapper EB, Challies T, Nasser I, Afdhal NH, Lai M. The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2016;111(5):677\u201384. https:\/\/doi.org\/10.1038\/ajg.2016.49.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10027_CR87","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cgh.2020.12.013","volume":"20","author":"A Paisant","year":"2022","unstructured":"Paisant A, Lemoine S, Cassinotto C, de Ledinghen V, Ronot M, Irles-Depe M, et al. Reliability criteria of two-dimensional shear wave elastography: analysis of 4277 measurements in 788 patients. Clin Gastroenterol Hepatol. 2022;20(2):400-8 e10. https:\/\/doi.org\/10.1016\/j.cgh.2020.12.013.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10027_CR88","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1111\/liv.15941","volume":"44","author":"EA Tsochatzis","year":"2024","unstructured":"Tsochatzis EA, Valenti L, Thiele M, Peloquin S, Lazure P, Masson MH, et al. Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: a qualitative exploration of challenges and barriers. Liver Int. 2024;44(8):1990\u20132001. https:\/\/doi.org\/10.1111\/liv.15941.","journal-title":"Liver Int"},{"issue":"1","key":"10027_CR89","doi-asserted-by":"publisher","DOI":"10.5812\/iranjradiol.17078","volume":"12","author":"SM Alavian","year":"2015","unstructured":"Alavian SM. Liver biopsy versus non-invasive tests in determining liver disease status. Iran J Radiol. 2015;12(1):e17078. https:\/\/doi.org\/10.5812\/iranjradiol.17078.","journal-title":"Iran J Radiol"},{"key":"10027_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101320","volume":"54","author":"JV Lazarus","year":"2025","unstructured":"Lazarus JV, Brennan PN, Mark HE, Alazawi W, Allen AM, Byrne CD, et al. A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis. The Lancet Regional Health - Europe. 2025;54:101320. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101320.","journal-title":"The Lancet Regional Health - Europe"},{"issue":"5","key":"10027_CR91","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.cgh.2023.12.018","volume":"22","author":"M Kjaergaard","year":"2024","unstructured":"Kjaergaard M, Lindvig KP, Thorhauge KH, Johansen S, Hansen JK, Andersen P, et al. Screening for fibrosis promotes lifestyle changes: a prospective cohort study in 4796 individuals. Clin Gastroenterol Hepatol. 2024;22(5):1037-47 e9. https:\/\/doi.org\/10.1016\/j.cgh.2023.12.018.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10027_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1316284","volume":"10","author":"MV Machado","year":"2023","unstructured":"Machado MV. MASLD treatment-a shift in the paradigm is imminent. Front Med (Lausanne). 2023;10:1316284. https:\/\/doi.org\/10.3389\/fmed.2023.1316284.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10027_CR93","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ueg2.12525","volume":"12","author":"J Zeng","year":"2024","unstructured":"Zeng J, Fan JG, Francque SM. Therapeutic management of metabolic dysfunction associated steatotic liver disease. United Eur Gastroenterol J. 2024;12(2):177\u201386. https:\/\/doi.org\/10.1002\/ueg2.12525.","journal-title":"United Eur Gastroenterol J"},{"issue":"1","key":"10027_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-01740-6","volume":"15","author":"M Kim","year":"2025","unstructured":"Kim M, Park H, Yoon EL, Cheung R, Kim D, Kim HL, et al. Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up. Sci Rep. 2025;15(1):19336. https:\/\/doi.org\/10.1038\/s41598-025-01740-6.","journal-title":"Sci Rep"},{"key":"10027_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/biom15020213","author":"N Theodorakis","year":"2025","unstructured":"Theodorakis N, Nikolaou M. From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework. Biomolecules. 2025;15(2). https:\/\/doi.org\/10.3390\/biom15020213.","journal-title":"Biomolecules"},{"issue":"1","key":"10027_CR96","doi-asserted-by":"publisher","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","volume":"19","author":"G Karim","year":"2023","unstructured":"Karim G, Bansal MB. Resmetirom: an orally administered, smallmolecule, liver-directed, beta-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. touchREV Endocrinol. 2023;19(1):60\u201370. https:\/\/doi.org\/10.17925\/EE.2023.19.1.60.","journal-title":"touchREV Endocrinol"},{"issue":"7","key":"10027_CR97","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/liv.15930","volume":"44","author":"S Petta","year":"2024","unstructured":"Petta S, Targher G, Romeo S, Pajvani UB, Zheng MH, Aghemo A, et al. The first MASH drug therapy on the horizon: current perspectives of resmetirom. Liver Int. 2024;44(7):1526\u201336. https:\/\/doi.org\/10.1111\/liv.15930.","journal-title":"Liver Int"},{"issue":"1","key":"10027_CR98","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2445780","volume":"57","author":"D Wang","year":"2025","unstructured":"Wang D, Miao J, Zhang L, Zhang L. Research advances in the diagnosis and treatment of MASLD\/MASH. Ann Med. 2025;57(1):2445780. https:\/\/doi.org\/10.1080\/07853890.2024.2445780.","journal-title":"Ann Med"},{"key":"10027_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, Huang Y, Xu B, Gu X, Huang J, Sun J, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735. https:\/\/doi.org\/10.1136\/bmj-2024-083735.","journal-title":"BMJ"},{"issue":"21","key":"10027_CR100","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, Ostergaard LH, Long MT, Kjaer MS, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"issue":"2","key":"10027_CR101","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-78 e5. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005.","journal-title":"Gastroenterology"},{"issue":"2","key":"10027_CR102","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4254\/wjh.v11.i2.138","volume":"11","author":"TL Laursen","year":"2019","unstructured":"Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, et al. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World J Hepatol. 2019;11(2):138\u201349. https:\/\/doi.org\/10.4254\/wjh.v11.i2.138.","journal-title":"World J Hepatol"},{"issue":"2","key":"10027_CR103","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hep.32358","volume":"76","author":"R Pais","year":"2022","unstructured":"Pais R, Aron-Wisnewsky J, Bedossa P, Ponnaiah M, Oppert JM, Siksik JM, et al. Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology. 2022;76(2):456\u201368. https:\/\/doi.org\/10.1002\/hep.32358.","journal-title":"Hepatology"},{"issue":"12","key":"10027_CR104","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.tem.2021.09.001","volume":"32","author":"G Milan","year":"2021","unstructured":"Milan G, Conci S, Sanna M, Favaretto F, Bettini S, Vettor R. ASCs and their role in obesity and metabolic diseases. Trends Endocrinol Metab. 2021;32(12):994\u20131006. https:\/\/doi.org\/10.1016\/j.tem.2021.09.001.","journal-title":"Trends Endocrinol Metab"},{"key":"10027_CR105","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-23-0180","author":"CM Gliniak","year":"2023","unstructured":"Gliniak CM, Pedersen L, Scherer PE. Adipose tissue fibrosis: the unwanted houseguest invited by obesity. J Endocrinol. 2023;259(3). https:\/\/doi.org\/10.1530\/JOE-23-0180.","journal-title":"J Endocrinol"},{"key":"10027_CR106","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-physiol-060721-092930","volume":"84","author":"G Marcelin","year":"2022","unstructured":"Marcelin G, Gautier EL, Clement K. Adipose tissue fibrosis in obesity: etiology and challenges. Annu Rev Physiol. 2022;84:135\u201355. https:\/\/doi.org\/10.1146\/annurev-physiol-060721-092930.","journal-title":"Annu Rev Physiol"},{"key":"10027_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155937","volume":"157","author":"M Huttasch","year":"2024","unstructured":"Huttasch M, Roden M, Kahl S. Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease? Metabolism. 2024;157:155937. https:\/\/doi.org\/10.1016\/j.metabol.2024.155937.","journal-title":"Metabolism"},{"issue":"6","key":"10027_CR108","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"key":"10027_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111846","volume":"217","author":"S Gancheva","year":"2024","unstructured":"Gancheva S, Roden M, Castera L. Diabetes as a risk factor for MASH progression. Diabetes Res Clin Pract. 2024;217:111846. https:\/\/doi.org\/10.1016\/j.diabres.2024.111846.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10027_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s44355-024-00017-5","volume":"2","author":"PN Brennan","year":"2025","unstructured":"Brennan PN, Kopka CJ, Agirre-Garrido L, Hansen CD, Alkhouri N, Schattenberg JM, et al. Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation\/accessibility of Resmetirom. npj Gut and Liver. 2025;2(1):3. https:\/\/doi.org\/10.1038\/s44355-024-00017-5.","journal-title":"npj Gut and Liver"},{"key":"10027_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2024.100386","volume":"41","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Husain M, Diab C, Mangla KK, Shoeb A, Lingvay I, et al. Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: a systematic review. Am Heart J Plus. 2024;41:100386. https:\/\/doi.org\/10.1016\/j.ahjo.2024.100386.","journal-title":"Am Heart J Plus"},{"key":"10027_CR112","unstructured":"Newsome PN, Armstrong MJ, Bakulin I, Belloum A, Cali AM, Geerts A, George J, Janczewska E, Krarup N, Liu CJ, Midgard H, Ratziu V, Rinella M, Roden M, Sanyal AJ, Schattenberg J, Tawfik M, Vestergaard TC, Bugianesi E. Weight-independent benefits of semaglutide on histology and non-invasive tests in participants with biopsy-defined MASH: post hoc analysis of the ESSENCE trial part 1. Obes Facts. 2025;18(Suppl 1):AS4. Abstract."},{"issue":"19","key":"10027_CR113","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"24","key":"10027_CR114","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"2","key":"10027_CR115","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"10437","key":"10027_CR116","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","volume":"403","author":"J Butler","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrom SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437):1635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(24)00469-0.","journal-title":"Lancet"},{"issue":"10454","key":"10027_CR117","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/s0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773\u201386. https:\/\/doi.org\/10.1016\/s0140-6736(24)01498-3.","journal-title":"Lancet"},{"issue":"10019","key":"10027_CR118","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X.","journal-title":"Lancet"},{"issue":"4","key":"10027_CR119","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"issue":"5","key":"10027_CR120","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med"},{"key":"10027_CR121","unstructured":"Eli Lilly and Company. Lilly\u2019s Mounjaro\u2122 (tirzepatide) demonstrates significant clinical outcomes. 2025. Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated. [Cited 2025 Aug]"},{"issue":"11","key":"10027_CR122","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","volume":"37","author":"H Taheri","year":"2020","unstructured":"Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Reza babaei M, et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther. 2020;37(11):4697\u2013708. https:\/\/doi.org\/10.1007\/s12325-020-01498-5.","journal-title":"Adv Ther"},{"issue":"15","key":"10027_CR123","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"16","key":"10027_CR124","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"12","key":"10027_CR125","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"issue":"21","key":"10027_CR126","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"15","key":"10027_CR127","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"2","key":"10027_CR128","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"E-KCG The","year":"2023","unstructured":"The E-KCG, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"issue":"1","key":"10027_CR129","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jhep.2024.06.034","volume":"82","author":"WS Silva Junior","year":"2025","unstructured":"Silva Junior WS, Sposito AC, Godoy-Matos A. Should the new EASL-EASD-EASO Clinical Practice Guidelines on MASLD recommend pioglitazone as a MASH-targeted pharmacotherapy? J Hepatol. 2025;82(1):e21\u20132. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.034.","journal-title":"J Hepatol"},{"issue":"3","key":"10027_CR130","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1210\/jc.2016-3237","volume":"102","author":"CM Viscoli","year":"2017","unstructured":"Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, et al. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab. 2017;102(3):914\u201322. https:\/\/doi.org\/10.1210\/jc.2016-3237.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10027_CR131","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305\u201315. https:\/\/doi.org\/10.7326\/M15-1774.","journal-title":"Ann Intern Med"},{"issue":"5","key":"10027_CR132","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","volume":"177","author":"G Musso","year":"2017","unstructured":"Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017;177(5):633\u201340. https:\/\/doi.org\/10.1001\/jamainternmed.2016.9607.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10027_CR133","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.numecd.2021.12.006","volume":"32","author":"E Mannucci","year":"2022","unstructured":"Mannucci E, Giaccari A, Gallo M, Targher G, Pintaudi B, Candido R, et al. Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2022;32(3):529\u201336. https:\/\/doi.org\/10.1016\/j.numecd.2021.12.006.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"10","key":"10027_CR134","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46911","volume":"15","author":"IM Sheikh","year":"2023","unstructured":"Sheikh IM, Hassan OA, Adam SM, Ali AI, Ogedegbe OJ, Tabowei G, et al. Association of pioglitazone with major adverse cardiovascular events, all-cause mortality, and heart failure hospitalizations: a systematic review. Cureus. 2023;15(10):e46911. https:\/\/doi.org\/10.7759\/cureus.46911.","journal-title":"Cureus"},{"key":"10027_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1420485","volume":"15","author":"YR Li","year":"2024","unstructured":"Li YR, Wang CC, Liu CH, Yen CL, Wu VC, Huang EJ, et al. Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone. Front Endocrinol (Lausanne). 2024;15:1420485. https:\/\/doi.org\/10.3389\/fendo.2024.1420485.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10027_CR136","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","volume":"36","author":"MA Tincopa","year":"2024","unstructured":"Tincopa MA, Anstee QM, Loomba R. New and emerging treatments for metabolic dysfunction-associated steatohepatitis. Cell Metab. 2024;36(5):912\u201326. https:\/\/doi.org\/10.1016\/j.cmet.2024.03.011.","journal-title":"Cell Metab"},{"issue":"1","key":"10027_CR137","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","volume":"22","author":"QM Anstee","year":"2024","unstructured":"Anstee QM, Neuschwander-Tetri BA, Wai-Sun Wong V, Abdelmalek MF, Rodriguez-Araujo G, Landgren H, et al. Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study. Clin Gastroenterol Hepatol. 2024;22(1):124-34 e1. https:\/\/doi.org\/10.1016\/j.cgh.2023.04.003.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10027_CR138","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26\u201339. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.027.","journal-title":"J Hepatol"},{"key":"10027_CR139","unstructured":"ClinicalTrials.gov. Phase 3 study to evaluate the efficacy and safety of elafibranor versus placebo in patients with nonalcoholic steatohepatitis (NCT02704403). Bethesda (MD): National Library of Medicine; 2016. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02704403. [Cited 2025 Aug]"},{"issue":"3","key":"10027_CR140","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","volume":"81","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Rolph T, Knott M, Dubourg J. FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond. J Hepatol. 2024;81(3):562\u201376. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.034.","journal-title":"J Hepatol"},{"issue":"4","key":"10027_CR141","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A phase 2 randomized trial of Survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2401755.","journal-title":"N Engl J Med"},{"issue":"7","key":"10027_CR142","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037\u201348. https:\/\/doi.org\/10.1038\/s41591-024-03018-2.","journal-title":"Nat Med"},{"issue":"1","key":"10027_CR143","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","volume":"23","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Frias JP, Lucas KJ, Reiss G, Neff G, Bollepalli S, et al. Safety and efficacy of Efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH\/MASH and type 2 diabetes in a randomized phase 2 study. Clin Gastroenterol Hepatol. 2025;23(1):103\u201313. https:\/\/doi.org\/10.1016\/j.cgh.2024.02.022.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10027_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04017-x","volume":"23","author":"M Lee","year":"2025","unstructured":"Lee M, Hong S, Cho Y, Rhee H, Yu MH, Bae J, et al. Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial. BMC Med. 2025;23(1):266. https:\/\/doi.org\/10.1186\/s12916-025-04017-x.","journal-title":"BMC Med"},{"issue":"5","key":"10027_CR145","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0302155","volume":"19","author":"YH Lin","year":"2024","unstructured":"Lin YH, Zhang ZJ, Zhong JQ, Wang ZY, Peng YT, Lin YM, et al. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: study protocol for a randomized clinical trial. PLoS One. 2024;19(5):e0302155. https:\/\/doi.org\/10.1371\/journal.pone.0302155.","journal-title":"PLoS One"},{"issue":"7","key":"10027_CR146","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/jdi.70066","volume":"16","author":"D Tsuriya","year":"2025","unstructured":"Tsuriya D, Kobayashi K, Takeshita K, Hashimoto T, Kimura M, Muta Y, et al. Liver function effects of SGLT2 inhibitor and GLP-1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study). J Diabetes Investig. 2025;16(7):1243\u201353. https:\/\/doi.org\/10.1111\/jdi.70066.","journal-title":"J Diabetes Investig"},{"key":"10027_CR147","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.02.044","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Zelber-Sagi S, Lazarus JV, Wong VW, Yilmaz Y, Duseja A, et al. Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology. 2025. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.044.","journal-title":"Gastroenterology"},{"issue":"7","key":"10027_CR148","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. a consensus report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057\u201382. https:\/\/doi.org\/10.2337\/dci24-0094.","journal-title":"Diabetes Care"},{"issue":"4","key":"10027_CR149","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.022.","journal-title":"J Hepatol"},{"issue":"3","key":"10027_CR150","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7812\/tpp\/23.134","volume":"28","author":"KC Maita","year":"2024","unstructured":"Maita KC, Maniaci MJ, Haider CR, Avila FR, Torres-Guzman RA, Borna S, et al. The impact of digital health solutions on bridging the health care gap in rural areas: a scoping review. Perm J. 2024;28(3):130\u201343. https:\/\/doi.org\/10.7812\/tpp\/23.134.","journal-title":"Perm J"},{"key":"10027_CR151","doi-asserted-by":"publisher","unstructured":"Zafar Y, Sohail MU, Saad M, Ahmed SZ, Sohail MO, Zafar J, et al. Ehealth interventions and patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2025;12(1). https:\/\/doi.org\/10.1136\/bmjgast-2024-001670.","DOI":"10.1136\/bmjgast-2024-001670"},{"key":"10027_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2020.04.025","volume":"125","author":"JJH Park","year":"2020","unstructured":"Park JJH, Harari O, Dron L, Lester RT, Thorlund K, Mills EJ. An overview of platform trials with a checklist for clinical readers. J Clin Epidemiol. 2020;125:1\u20138. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.04.025.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10027_CR153","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cjco.2019.12.002","volume":"2","author":"A Langer","year":"2020","unstructured":"Langer A, Tan M, Goodman SG, Gregoire J, Lin PJ, Mancini GBJ, et al. GOAL Canada: physician education and support can improve patient management. CJC Open. 2020;2(2):49\u201354. https:\/\/doi.org\/10.1016\/j.cjco.2019.12.002.","journal-title":"CJC Open"},{"issue":"8S","key":"10027_CR154","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.cjca.2024.05.010","volume":"40","author":"G Marquis-Gravel","year":"2024","unstructured":"Marquis-Gravel G, Bhatia S, Brown V, Goodman SG. Care gaps and system issues with delivering cardiovascular risk reduction and lipid-lowering therapy in secondary prevention. Can J Cardiol. 2024;40(8S):S35-42. https:\/\/doi.org\/10.1016\/j.cjca.2024.05.010.","journal-title":"Can J Cardiol"},{"key":"10027_CR155","doi-asserted-by":"publisher","DOI":"10.2196\/49115","volume":"7","author":"J Okemah","year":"2023","unstructured":"Okemah J, Neunie S, Noble A, Wysham C. Impact on knowledge, competence, and performance of a faculty-led web-based educational activity for type 2 diabetes and obesity: questionnaire study among health care professionals and analysis of anonymized patient records. JMIR Form Res. 2023;7:e49115. https:\/\/doi.org\/10.2196\/49115.","journal-title":"JMIR Form Res"},{"key":"10027_CR156","doi-asserted-by":"publisher","unstructured":"Stine JG, Bradley D, McCall-Hosenfeld J, Motz-Patel V, Tondt J, Batra S, et al. Multidisciplinary clinic model enhances liver and metabolic health outcomes in adults with MASH. Hepatol Commun. 2025;9(2). https:\/\/doi.org\/10.1097\/HC9.0000000000000649.","DOI":"10.1097\/HC9.0000000000000649"},{"key":"10027_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100706","volume":"19","author":"T Modarressi","year":"2024","unstructured":"Modarressi T. Role and impact of a specialized cardiometabolic clinic in managing high-risk patients with type 2 diabetes and atherosclerotic cardiovascular disease. Am J Prev Cardiol. 2024;19:100706. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100706.","journal-title":"Am J Prev Cardiol"},{"key":"10027_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2022.880468","volume":"3","author":"Y Manla","year":"2022","unstructured":"Manla Y, Almahmeed W. Cardiometabolic clinics: is there a need for a multidisciplinary clinic? Front Clin Diabetes Healthc. 2022;3:880468. https:\/\/doi.org\/10.3389\/fcdhc.2022.880468.","journal-title":"Front Clin Diabetes Healthc"},{"issue":"12","key":"10027_CR159","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/j.numecd.2024.09.004","volume":"34","author":"HH Habte-Asres","year":"2024","unstructured":"Habte-Asres HH, Hou C, Forbes A, Wheeler DC. Organisational initiatives to improve care in the prevention and management of cardiometabolic conditions: a scoping review. Nutr Metab Cardiovasc Dis. 2024;34(12):2630\u201341. https:\/\/doi.org\/10.1016\/j.numecd.2024.09.004.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"10027_CR160","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251741","volume":"16","author":"SE Congly","year":"2021","unstructured":"Congly SE, Shaheen AA, Swain MG. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting. PLoS One. 2021;16(5):e0251741. https:\/\/doi.org\/10.1371\/journal.pone.0251741.","journal-title":"PLoS One"},{"key":"10027_CR161","doi-asserted-by":"publisher","unstructured":"Kim J, Ito T, Arai T, Atsukawa M, Kawanaka M, Toyoda H, et al. Modified FIB-4 index in type 2 diabetes mellitus with steatosis: a non-linear predictive model for advanced hepatic fibrosis. Diagnostics (Basel). 2024(22). https:\/\/doi.org\/10.3390\/diagnostics14222500.","DOI":"10.3390\/diagnostics14222500"},{"issue":"1","key":"10027_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhsg.2023.06.016","volume":"6","author":"SH Liu","year":"2024","unstructured":"Liu SH, Burgan J, Ling K, Loyst RA, Tantone R, Komatsu DE, et al. Aspartate aminotransferase-to-platelet ratio index suggestive of liver dysfunction predicts early complications after open reduction internal fixation of distal radius fractures. J Hand Surg Glob Online. 2024;6(1):1\u20135. https:\/\/doi.org\/10.1016\/j.jhsg.2023.06.016.","journal-title":"J Hand Surg Glob Online"},{"key":"10027_CR163","doi-asserted-by":"publisher","first-page":"797","DOI":"10.36348\/sjmps.2023.v09i12.004","volume":"9","author":"F Bouhamou","year":"2023","unstructured":"Bouhamou F, Salihoun M, Serraj I, Kabbaj N. FIB-4, APRI, and NFS scores compared to FibroScan for the assessment of liver fibrosis in patients with NAFLD. Saudi J Med Pharm Sci. 2023;9:797\u2013801. https:\/\/doi.org\/10.36348\/sjmps.2023.v09i12.004.","journal-title":"Saudi J Med Pharm Sci"},{"issue":"1","key":"10027_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01400-1","volume":"20","author":"SM Schmitz","year":"2020","unstructured":"Schmitz SM, Kroh A, Ulmer TF, Andruszkow J, Luedde T, Brozat JF, et al. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems. BMC Gastroenterol. 2020;20(1):254. https:\/\/doi.org\/10.1186\/s12876-020-01400-1.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10027_CR165","doi-asserted-by":"publisher","first-page":"e624","DOI":"10.1016\/j.cgh.2021.01.010","volume":"20","author":"A Singh","year":"2022","unstructured":"Singh A, Garg R, Lopez R, Alkhouri N. Diabetes liver fibrosis score to detect advanced fibrosis in diabetics with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20(3):e624-6. https:\/\/doi.org\/10.1016\/j.cgh.2021.01.010.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10027_CR166","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cgh.2022.02.059","volume":"21","author":"J Boursier","year":"2023","unstructured":"Boursier J, Canivet CM, Costentin C, Lannes A, Delamarre A, Sturm N, et al. Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications. Clin Gastroenterol Hepatol. 2023;21(5):1243-51.e12. https:\/\/doi.org\/10.1016\/j.cgh.2022.02.059.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl","key":"10027_CR167","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.3350\/cmh.2022.0336","volume":"29","author":"S Zhang","year":"2023","unstructured":"Zhang S, Mak LY, Yuen MF, Seto WK. Screening strategy for non-alcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S103\u201322. https:\/\/doi.org\/10.3350\/cmh.2022.0336.","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10027_CR168","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s00261-024-04546-8","volume":"50","author":"R Yamaguchi","year":"2025","unstructured":"Yamaguchi R, Oda T, Nagashima K. Comparison of the diagnostic accuracy of shear wave elastography with transient elastography in adult nonalcoholic fatty liver disease: a systematic review and network meta-analysis of diagnostic test accuracy. Abdom Radiol (NY). 2025;50(2):734\u201346. https:\/\/doi.org\/10.1007\/s00261-024-04546-8.","journal-title":"Abdom Radiol (NY)"},{"issue":"5","key":"10027_CR169","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11547-022-01475-8","volume":"127","author":"G Argalia","year":"2022","unstructured":"Argalia G, Ventura C, Tosi N, Campioni D, Tagliati C, Tufillaro M, et al. Comparison of point shear wave elastography and transient elastography in the evaluation of patients with NAFLD. Radiol Med. 2022;127(5):571\u20136. https:\/\/doi.org\/10.1007\/s11547-022-01475-8.","journal-title":"Radiol Med"},{"issue":"1","key":"10027_CR170","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/hep.29179","volume":"67","author":"E Herrmann","year":"2018","unstructured":"Herrmann E, de L\u00e9dinghen V, Cassinotto C, Chu WC, Leung VY, Ferraioli G, et al. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis. Hepatology. 2018;67(1):260\u201372. https:\/\/doi.org\/10.1002\/hep.29179.","journal-title":"Hepatology"},{"issue":"10","key":"10027_CR171","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.72471","volume":"16","author":"D Arun Kumar","year":"2024","unstructured":"Arun Kumar D, Kumar S, Rajagopal R, Ramesh R, Manoj M. Non-invasive assessment of liver fibrosis using shear wave elastography in patients with type 2 diabetes mellitus having non-alcoholic fatty liver disease. Cureus. 2024;16(10):e72471. https:\/\/doi.org\/10.7759\/cureus.72471.","journal-title":"Cureus"},{"issue":"3","key":"10027_CR172","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cgh.2014.09.046","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh S, Venkatesh SK, Wang Z, Miller FH, Motosugi U, Low RN, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 2015;13(3):440-51 e6. https:\/\/doi.org\/10.1016\/j.cgh.2014.09.046.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10027_CR173","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","volume":"21","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Castera L, Wong VW. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023;21(8):2026\u201339. https:\/\/doi.org\/10.1016\/j.cgh.2023.03.042.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10027_CR174","doi-asserted-by":"publisher","unstructured":"Kang YW, Baek YH, Moon SY. Sequential diagnostic approach using FIB-4 and ELF for predicting advanced fibrosis in metabolic dysfunction-associated steatotic liver disease. Diagnostics (Basel). 2024;14(22). https:\/\/doi.org\/10.3390\/diagnostics14222517.","DOI":"10.3390\/diagnostics14222517"},{"issue":"4","key":"10027_CR175","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.cgh.2023.11.022","volume":"22","author":"T Arai","year":"2024","unstructured":"Arai T, Takahashi H, Seko Y, Toyoda H, Hayashi H, Yamaguchi K, et al. Accuracy of the enhanced liver fibrosis test in patients with type 2 diabetes mellitus and its clinical implications. Clin Gastroenterol Hepatol. 2024;22(4):789-97 e8. https:\/\/doi.org\/10.1016\/j.cgh.2023.11.022.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10027_CR176","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s11695-017-2606-9","volume":"27","author":"IC Lopez","year":"2017","unstructured":"Lopez IC, Aroca FG, Bernal MDF, Mompean JAL, Bernal AB, Martinez AMH, et al. Utility of the ELF test for detecting steatohepatitis in morbid obese patients with suspicion of nonalcoholic fatty liver disease. Obes Surg. 2017;27(9):2347\u201353. https:\/\/doi.org\/10.1007\/s11695-017-2606-9.","journal-title":"Obes Surg"}],"updated-by":[{"DOI":"10.1007\/s11154-026-10064-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000}}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-026-10027-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-026-10027-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-026-10027-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:54:33Z","timestamp":1782280473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-026-10027-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":176,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10027"],"URL":"https:\/\/doi.org\/10.1007\/s11154-026-10027-8","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised as some data included in the main text should be a part of figure 1 and figure 2 caption.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11154-026-10064-3","URL":"https:\/\/doi.org\/10.1007\/s11154-026-10064-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.V. declares research grants from Pfizer; fees for educational purposes from Novo Nordisk, AstraZeneca, and Eli Lilly; and serving on scientific advisory boards for Eli Lilly and Novo Nordisk (ORCID 0000-0003-0625-6667). M.L.P. declares serving on advisory boards for Novo Nordisk and Theras; and fees for lectures from Eli Lilly, Novo Nordisk, and Bruno Farmaceutici (ORCID 0000-0002-7040-6466). I.D. declares research grants from AstraZeneca and Merck; fees for educational lectures from Novo Nordisk, AstraZeneca, Gefen Medical, Abbott, Boehringer Ingelheim, Sanofi, and Eli Lilly; and serving on scientific advisory boards for Eli Lilly, Boehringer Ingelheim, Sanofi, Novartis, Abbott, and Novo Nordisk (ORCID 0000-0003-0551-4759). G.L. declares consulting fees from Briya, Rafaa, and Ayala pharmaceuticals; and fees for lectures from Novo Nordisk, Hoffman La-Roche, and AstraZeneca (ORCID 0000-0001-7392-3082). M.Hal. declares serving on the advisory panel for Eli Lilly, Novo Nordisk, Sanofi, AstraZeneca, Mundipharma; serving as a consultant for Eli Lilly, Novo Nordisk, Sanofi, Astra Zeneca, and Mundipharma; receiving research support from AstraZeneca, Eli Lilly, and Bristol-Meyers Squibb; and receiving honoraria or consulting fees from Amgen, AstraZeneca, Boehringer Ingelheim, Berlin Chemie, Eli Lilly, Janssen, Johnson & Johnson, Zentiva, and Merck (ORCID 0000-0002-0201-6888). C.W.S. declares receiving fees for educational purposes from Sanofi and Novo Nordisk (ORCID: 0000-0003-3199-301). J.A.D. declares receiving grants, serving on advisory boards and receiving fees for educational lectures from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Novo Nordisk, Roche, Sanofi, and Servier (ORCID 0000-0003-3084-7408). F.A. declares no conflicts of interest (ORCID 0000-0003-4495-7704). S.A. declares receiving grants\/research support from Novo Nordisk and Sanofi; serving on advisory boards and\/or Speakers Bureau for AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, and Sanofi; and serving as a speaker for Novo Nordisk, Boehringer Ingelheim, Bayer, Servier, Novartis, and Saja Pharma (ORCID 0000-0001-6546-8622). A.A. declares research grants from Novo Nordisk; and advisory boards fees for educational purposes from Novo Nordisk, AstraZeneca, Sanofi, Amgen, Algorithm, and Eli Lilly (ORCID: 0000-0001-9726-7753). R.B. declares serving on an advisory board for Boehringer Ingelheim; and receiving fees for lectures from Novo Nordisk (ORCID 0000-0001-9924-4301). M.Har. declares no conflicts of interest (ORCID 0000-0001-9761-9595). A.J. declares no conflicts of interest (ORCID: 0000-0001-9726-7753). M.K. declares no conflicts of interest (ORICD 0000-0002-7900-1094). S.K. declares no conflicts of interest (ORICD 0000-0003-3574-071). V.L. declares receiving honoraria for advisory boards, research grants, clinical trials, speakers\u2019 bureau, and consulting from Novartis, Sanofi, Novo Nordisk, MSD, Eli Lilly, Boehringer Ingelheim, Vianex, AstraZeneca, Mylan, Amgen, ELPEN, Amryt, Medtronic, Menarini, Bios, and Abbott (ORCID 0000-0002-4620-4039). G.P. declares serving as an advisor and\/or lecturer for AbbVie, Albireo, Amgen, Astra-Zeneca, BioARS, Elpen, Genesis, Gilead, GlaxoSmithKline, Ipsen, Janssen, Merck Sharp & Dohme, Novo Nordisk, Roche, Takeda, and Vir Pharmaceuticals; and receiving research grants from AbbVie, Gilead, Takeda, and Vianex (ORCID 0000-0002-3518-4060). M.P. declares serving on an advisory board for Grifols; and receiving fees for lectures from Novo Nordisk (ORCID 0000-0003-3662-4010). S.P. declares serving as a speaker and\/or advisor for Boehringer Ingelheim, Echosens, Madrigal, Novo Nordisk, Pfizer, and Resalis (ORCID 0000-0002-0822-9673). C.S.P. declares no conflicts of interest (ORCID 0000-0001-8739-1961). A.P.S. declares serving on advisory boards for Astra Zeneca, Merck, Medtronic, Novo Nordisk, Roche Diabetes, and Sanofi; serving as an investigator on clinical trials CREDANCE, REIMAGINE2, and ZEUS; and receiving speaker or consultant fees from Amgen, AstraZeneca, Coca-Cola, MSD, Medtronic, Dexcom, Roche Diabetes, Novo Nordisk, Novartis, Eli Lilly, Boehringer Ingelheim, Sanofi, Servier, and Worvag (ORCID 0000-0003-0555-526). K.T. declares receiving research grants from AbbVie and Gilead; and receiving fees for lectures and serving on advisory boards for Alfa Sigma, AstraZeneca, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Pfizer, Novo Nordisk, Promed, Bausch Healthcare, and Takeda (ORCID 0000-0001-7868-2708).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}